New diabetes clinical trial: Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
Published on: 2026-03-09T04:00:00Z
Conditions: Diabetic Macular Edema (DME); Age-Related Macular Degeneration (AMD); Retinal Vein Occlusion; Diabetic Retinopathy (DR)
Interventions: Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO); Procedure: Sham Subconjunctival Injection; Drug: Proparacaine Hydrochloride Ophthalmic Solution 0.5%; Drug: Lidocaine Hydrochloride Injection 2%
Sponsors: Harrow Inc
Not yet recruiting
https://ift.tt/aqoJm6G
Conditions: Diabetic Macular Edema (DME); Age-Related Macular Degeneration (AMD); Retinal Vein Occlusion; Diabetic Retinopathy (DR)
Interventions: Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO); Procedure: Sham Subconjunctival Injection; Drug: Proparacaine Hydrochloride Ophthalmic Solution 0.5%; Drug: Lidocaine Hydrochloride Injection 2%
Sponsors: Harrow Inc
Not yet recruiting
https://ift.tt/aqoJm6G
Comments
Post a Comment